RALGAPA2 encodes the catalytic alpha subunit of the RalGAP2 complex, which functions as a GTPase activating protein that negatively regulates RalA and RalB small GTPases 1. The protein forms an obligatory heterodimer with RalGAPβ, and these heterodimers assemble into extended tetrameric complexes that are essential for in vivo function 2. As a tumor suppressor, RALGAPA2 inhibits oncogenic Ras signaling pathways by promoting GTP hydrolysis in RalA/B GTPases 13. Loss or downregulation of RALGAPA2 has significant clinical implications across multiple cancers. In hepatocellular carcinoma, RALGAPA2 downregulation combined with RalA upregulation correlates with aggressive tumor behavior, venous invasion, advanced staging, and poor overall survival 1. Similarly, reduced RALGAPA2 expression in prostate cancer promotes cellular invasion and progression from intraepithelial neoplasia to invasive adenocarcinoma 3. Forward genetic screens have validated RALGAPA2 as a bona fide tumor suppressor, with knockdown enhancing proliferation in multiple cancer cell lines 4. The therapeutic potential of targeting this pathway is supported by studies showing that Ral inhibition sensitizes cancer cells to existing treatments like sorafenib 14.